title: Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
authors.forename: Gemma
authors.initials: G
authors.lastname: Azaceta
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: Victoria
authors.initials: V
authors.lastname: Dourdil
authors.forename: Elena
authors.initials: E
authors.lastname: Bonafonte
authors.forename: Isabel
authors.initials: I
authors.lastname: Izquierdo
authors.forename: Luis
authors.initials: L
authors.lastname: Palomera
mesh_terms: D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D000077269:Lenalidomide; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide